These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27346829)

  • 81. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy.
    Kaehler KC; Gutzmer R; Egberts F; Hauschild A
    J Dtsch Dermatol Ges; 2014 Oct; 12(10):906-7. PubMed ID: 25041591
    [No Abstract]   [Full Text] [Related]  

  • 82. Four-year experience with vismodegib hedgehog inhibitor therapy.
    Simone PD; Schwarz JM; Strasswimmer JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1264-5. PubMed ID: 27185433
    [No Abstract]   [Full Text] [Related]  

  • 83. A massive neglected giant basal cell carcinoma in a schizophrenic patient treated successfully with vismodegib.
    Andersen RM; Lei U
    J Dermatolog Treat; 2015; 26(6):575-6. PubMed ID: 25909367
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

  • 85. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
    Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
    Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma.
    Marescassier H; Dousset L; Beylot-Barry M; Célérier P; Vaillant L; Bedane C; Leclère F; Wierzbicka-Hainaut E; Masson Regnault M
    Dermatology; 2021; 237(6):1023-1028. PubMed ID: 33472195
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
    Sofen H; Gross KG; Goldberg LH; Sharata H; Hamilton TK; Egbert B; Lyons B; Hou J; Caro I
    J Am Acad Dermatol; 2015 Jul; 73(1):99-105.e1. PubMed ID: 25913533
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
    Verkouteren BJA; Wakkee M; Reyners AKL; Nelemans P; Aarts MJB; Rácz E; Terra JB; Devriese LA; Alers RJ; Kapiteijn E; van Doorn R; Bekkenk MW; Reinders MGHC; Mosterd K
    Br J Cancer; 2021 Mar; 124(7):1199-1206. PubMed ID: 33462360
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Advanced treatment for basal cell carcinomas.
    Atwood SX; Whitson RJ; Oro AE
    Cold Spring Harb Perspect Med; 2014 Jul; 4(7):a013581. PubMed ID: 24985127
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice.
    Khoo AB; Ali FR; Lear JT
    Curr Opin Oncol; 2016 Mar; 28(2):180-4. PubMed ID: 26780190
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 92. Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study.
    Bossi P; Peris K; Calzavara-Pinton P; Queirolo P; Alfieri S; Palla M; Rossi MT; Spagnolo F; Tambone S; Astolfi C; Ascierto PA
    Future Oncol; 2020 Jun; 16(16):1091-1100. PubMed ID: 32374193
    [No Abstract]   [Full Text] [Related]  

  • 93. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma.
    Paulsen JF; Øregaard JS; Nielsen AL; Gehl J; Venzo A
    Acta Oncol; 2016 Dec; 55(12):1492-1494. PubMed ID: 27448604
    [No Abstract]   [Full Text] [Related]  

  • 94. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

  • 95. Indications and limitations of vismodegib for basal cell carcinoma--reply.
    Gill HS; Moscato EE; Silkiss RZ
    JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
    [No Abstract]   [Full Text] [Related]  

  • 96. Vismodegib resistance in basal cell carcinoma: not a smooth fit.
    Ridky TW; Cotsarelis G
    Cancer Cell; 2015 Mar; 27(3):315-6. PubMed ID: 25759014
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacologic treatment options for advanced epithelial skin cancer.
    Soura E; Chasapi V; Stratigos AJ
    Expert Opin Pharmacother; 2015; 16(10):1479-93. PubMed ID: 26027692
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Expression of NCAM (CD56), chromogranin A, synaptophysin, c-KIT (CD117) and PDGFRA in normal non-neoplastic skin and basal cell carcinoma: an immunohistochemical study of 66 consecutive cases.
    Terada T
    Med Oncol; 2013 Mar; 30(1):444. PubMed ID: 23292839
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Current landscape for treatment of advanced basal cell carcinoma.
    Foley P
    Australas J Dermatol; 2015 Mar; 56 Suppl 1():1-7. PubMed ID: 25715811
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application.
    Tang JC; Hanke CW; Caro I
    J Drugs Dermatol; 2018 May; 17(5):506-508. PubMed ID: 29742180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.